Moreover, under hypobaric hypoxia, compared to the KN93 group (1.16 ± 0.05), the TMP_KN93 group (1.14 ± 0.21) had similar average RV wall thickness (Holm–Sidak’s test, p > 0.05) (Figure 7C), demonstrating that TMP treatment did not further decrease the RV wall thickness when utilized together with KN93 compared to KN93 alone; thus, TMP alleviates hypobaric hypoxia-induced cardiac hypertrophy through inhibiting CaMKII activation. This evidence concerns the gene CAMK2G and cardiac hypertrophy.